Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PHLDB2

Gene summary for PHLDB2

Gene summary.

Gene information	Species	Human
	Gene symbol	PHLDB2
	Gene ID	90102
	Gene name	pleckstrin homology like domain family B member 2
	Gene Alias	LL5b
	Cytomap	3q13.2
	Gene Type	protein-coding
	GO ID	GO:0000226
	UniProtAcc	Q86SQ0

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
90102	PHLDB2	CCI_1	Human	Cervix	CC	1.53e-03	9.03e-01	0.528
90102	PHLDB2	CCI_3	Human	Cervix	CC	7.19e-05	6.17e-01	0.516
90102	PHLDB2	CCII_1	Human	Cervix	CC	7.87e-06	3.42e-01	0.3249
90102	PHLDB2	sample1	Human	Cervix	CC	3.20e-22	8.14e-01	0.0959
90102	PHLDB2	T1	Human	Cervix	CC	6.64e-45	9.32e-01	0.0918
90102	PHLDB2	LZE4T	Human	Esophagus	ESCC	1.39e-33	1.16e+00	0.0811
90102	PHLDB2	LZE7T	Human	Esophagus	ESCC	6.41e-08	1.60e+00	0.0667
90102	PHLDB2	LZE8T	Human	Esophagus	ESCC	3.86e-08	3.59e-01	0.067
90102	PHLDB2	LZE20T	Human	Esophagus	ESCC	4.68e-02	1.11e-01	0.0662
90102	PHLDB2	LZE21T	Human	Esophagus	ESCC	5.44e-07	3.37e-01	0.0655
90102	PHLDB2	P2T-E	Human	Esophagus	ESCC	5.40e-04	-1.07e-01	0.1177
90102	PHLDB2	P4T-E	Human	Esophagus	ESCC	1.44e-16	7.51e-01	0.1323
90102	PHLDB2	P5T-E	Human	Esophagus	ESCC	1.71e-14	5.23e-01	0.1327
90102	PHLDB2	P9T-E	Human	Esophagus	ESCC	2.88e-34	1.29e+00	0.1131
90102	PHLDB2	P10T-E	Human	Esophagus	ESCC	3.36e-07	2.54e-01	0.116
90102	PHLDB2	P11T-E	Human	Esophagus	ESCC	1.31e-24	1.24e+00	0.1426
90102	PHLDB2	P12T-E	Human	Esophagus	ESCC	3.70e-04	2.27e-01	0.1122
90102	PHLDB2	P15T-E	Human	Esophagus	ESCC	2.04e-23	6.81e-01	0.1149
90102	PHLDB2	P16T-E	Human	Esophagus	ESCC	3.44e-09	5.54e-02	0.1153
90102	PHLDB2	P17T-E	Human	Esophagus	ESCC	2.22e-06	4.54e-01	0.1278

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00705076	Prostate	BPH	regulation of microtubule cytoskeleton organization	48/3107	148/18723	1.57e-06	2.67e-05	48
GO:00071628	Prostate	BPH	negative regulation of cell adhesion	82/3107	303/18723	2.51e-06	4.04e-05	82
GO:006104110	Prostate	BPH	regulation of wound healing	44/3107	134/18723	2.91e-06	4.61e-05	44
GO:190303416	Prostate	BPH	regulation of response to wounding	51/3107	167/18723	5.43e-06	8.01e-05	51
GO:00512715	Prostate	BPH	negative regulation of cellular component movement	94/3107	367/18723	6.18e-06	9.00e-05	94
GO:005149410	Prostate	BPH	negative regulation of cytoskeleton organization	49/3107	163/18723	1.32e-05	1.74e-04	49
GO:20001465	Prostate	BPH	negative regulation of cell motility	91/3107	359/18723	1.34e-05	1.76e-04	91
GO:00018376	Prostate	BPH	epithelial to mesenchymal transition	47/3107	157/18723	2.21e-05	2.67e-04	47
GO:00400135	Prostate	BPH	negative regulation of locomotion	96/3107	391/18723	3.11e-05	3.54e-04	96
GO:001063916	Prostate	BPH	negative regulation of organelle organization	87/3107	348/18723	3.56e-05	3.90e-04	87
GO:00303365	Prostate	BPH	negative regulation of cell migration	86/3107	344/18723	3.93e-05	4.25e-04	86
GO:00328862	Prostate	BPH	regulation of microtubule-based process	64/3107	240/18723	4.93e-05	5.11e-04	64
GO:00717113	Prostate	BPH	basement membrane organization	14/3107	31/18723	1.84e-04	1.54e-03	14
GO:00487626	Prostate	BPH	mesenchymal cell differentiation	61/3107	236/18723	1.88e-04	1.55e-03	61
GO:00073696	Prostate	BPH	gastrulation	50/3107	185/18723	2.20e-04	1.78e-03	50
GO:00514976	Prostate	BPH	negative regulation of stress fiber assembly	14/3107	32/18723	2.77e-04	2.16e-03	14
GO:00604854	Prostate	BPH	mesenchyme development	71/3107	291/18723	3.82e-04	2.81e-03	71
GO:00322326	Prostate	BPH	negative regulation of actin filament bundle assembly	14/3107	35/18723	8.33e-04	5.41e-03	14
GO:00108124	Prostate	BPH	negative regulation of cell-substrate adhesion	22/3107	68/18723	1.04e-03	6.52e-03	22
GO:0010717	Prostate	BPH	regulation of epithelial to mesenchymal transition	28/3107	99/18723	2.42e-03	1.31e-02	28

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PHLDB2

SNV

Missense_Mutation

novel

c.1172N>T

p.Asp391Val

p.D391V

Q86SQ0

protein_coding

deleterious(0)

benign(0.203)

TCGA-A7-A425-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

adriamycin

PHLDB2

SNV

Missense_Mutation

novel

c.3502N>A

p.Asp1168Asn

p.D1168N

Q86SQ0

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHLDB2

SNV

Missense_Mutation

c.359N>A

p.Gly120Glu

p.G120E

Q86SQ0

protein_coding

tolerated_low_confidence(0.09)

benign(0.018)

TCGA-AR-A250-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

PHLDB2

SNV

Missense_Mutation

c.1708N>G

p.Ile570Val

p.I570V

Q86SQ0

protein_coding

tolerated(0.1)

benign(0.255)

TCGA-B6-A0WV-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHLDB2

SNV

Missense_Mutation

c.604C>T

p.Pro202Ser

p.P202S

Q86SQ0

protein_coding

deleterious(0)

possibly_damaging(0.549)

TCGA-BH-A1FU-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PHLDB2

SNV

Missense_Mutation

c.1690N>C

p.Glu564Gln

p.E564Q

Q86SQ0

protein_coding

deleterious(0.05)

benign(0.388)

TCGA-BH-A209-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHLDB2

SNV

Missense_Mutation

c.1608N>T

p.Arg536Ser

p.R536S

Q86SQ0

protein_coding

tolerated(0.07)

benign(0.057)

TCGA-D8-A1XG-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

PHLDB2

SNV

Missense_Mutation

c.3134N>T

p.Ala1045Val

p.A1045V

Q86SQ0

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-D8-A1XK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine+cyclophosphamide

PHLDB2

SNV

Missense_Mutation

novel

c.7N>A

p.Glu3Lys

p.E3K

Q86SQ0

protein_coding

deleterious_low_confidence(0)

benign(0.214)

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

PHLDB2

SNV

Missense_Mutation

novel

c.3132N>T

p.Gln1044His

p.Q1044H

Q86SQ0

protein_coding

deleterious(0)

possibly_damaging(0.885)

TCGA-LQ-A4E4-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozole

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1